Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
meningococcal B rLP2086 vaccine candidate · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months |
| Name | Type | Description |
|---|---|---|
| meningococcal B rLP2086 vaccine candidate | BIOLOGICAL | vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months |
| Blood draw | PROCEDURE | Blood draw |
Inclusion Criteria: * Healthy male or female subject between the ages of \>=18 and \<=40 years * Negative urine pregnancy test for all female subjects of childbearing potential prior to test article administration and at the completion of the study. * All female or male subjects who are biologicall...
Meningococcal B rLP2086 vaccine candidate is an investigational vaccine being studied for the prevention of meningitis and meningococcal disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Meningococcal B rLP2086 vaccine candidate is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
Meningococcal B rLP2086 vaccine candidate is in Phase 1 clinical development. It is an investigational vaccine and has not been approved for use. One Phase 1 trial has been completed.
Meningococcal B rLP2086 vaccine candidate has one completed clinical trial, NCT00780806, titled 'Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults'. This Phase 1 study enrolled 60 participants in Australia and evaluated safety and blood collection.
Meningococcal B rLP2086 vaccine candidate is designed to elicit an immune response against Neisseria meningitidis serogroup B, the bacteria that causes meningococcal disease. It is intended to stimulate the production of antibodies that can neutralize the bacteria.